Firms

DCI Partners

DCI Partners

daiwa-inv.co.jp

Tokyo-based biotechnology venture capital firm founded in May 2014 within the Daiwa Corporate Investment group. It invests in Japanese and Taiwanese drug-discovery and regenerative-medicine companies and helps commercialize academic research. Alongside financing existing ventures, it creates new biotech companies around research programs and supports clinical development, intellectual property, licensing, recruitment and business development. Its third Japan–Taiwan biotech fund was announced in June 2026.

Founded
2014
Type
Venture capital

Funds1

  • Daiwa Taiwan-Japan BioVenture Investment Limited Partnership III—

    Third Japan–Taiwan biotechnology venture fund, announced June 30, 2026 as 大和日台バイオベンチャー3号投資事業有限責任組合. It backs private drug-discovery companies and creates new ventures around scientific programs, supporting development, licensing and partnerships across Japan and Taiwan. The issuer confirms commitments exceeding the previous ¥15.3 billion vehicle and plans to expand commitments to ¥25 billion, but does not disclose an exact current total. Its legal general partners are DCIP3 Co., Ltd., a wholly owned DCI Partners subsidiary, and DCIP3 Limited Liability Partnership. The vehicle has a ten-year operating term and five-year investment period.

Team

Operations and support

Hans YangTaipei Team Member (DCI)
Haruyo TakanoAudit & Supervisory Board Member
Hiroki NaritaFounder, President & CEO
Junichi YokotaTeam Member
Katsumi UchidaSenior Managing Director
Kohei KatayamaTeam Member
LingLing LiuTeam Member
Norihide HayakawaTeam Member
Ryoga KawanamiTeam Member
Satoshi MotomuraTaipei Team Member (DCI)
Shoma TanakaTeam Member
Shuntaro KodamaCo-founder, Senior Managing Director
Wei Fan ChenTaipei Team Member
Yuka NiimiTeam Member

Co-investing

Investments